bluebird bio Inc (NASDAQ:BLUE) – Analysts at Leerink Swann raised their FY2017 earnings per share (EPS) estimates for shares of bluebird bio in a research report issued on Thursday, according to Zacks Investment Research. Leerink Swann analyst M. Schmidt now forecasts that the biotechnology company will earn ($6.86) per share for the year, up from their prior estimate of ($6.90). Leerink Swann has a “Market Perform” rating and a $194.00 price objective on the stock. Leerink Swann also issued estimates for bluebird bio’s Q4 2017 earnings at ($1.72) EPS, Q2 2018 earnings at ($1.78) EPS, Q3 2018 earnings at ($1.86) EPS, Q4 2018 earnings at ($1.94) EPS, FY2018 earnings at ($7.25) EPS, FY2019 earnings at ($7.95) EPS and FY2020 earnings at ($5.33) EPS.
A number of other research firms have also weighed in on BLUE. Canaccord Genuity reaffirmed a “buy” rating and issued a $250.00 price objective on shares of bluebird bio in a research note on Thursday, February 1st. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $242.00 price objective (up from $190.00) on shares of bluebird bio in a research note on Tuesday, December 12th. SunTrust Banks raised their price objective on shares of bluebird bio to $223.00 and gave the company a “buy” rating in a research note on Tuesday, December 12th. BidaskClub raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 26th. Finally, Barclays reaffirmed an “overweight” rating and issued a $209.00 price objective (up from $162.00) on shares of bluebird bio in a research note on Wednesday, December 13th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $161.45.
bluebird bio (NASDAQ BLUE) opened at $197.50 on Monday. bluebird bio has a 12 month low of $73.95 and a 12 month high of $222.03. The firm has a market cap of $9,050.00, a price-to-earnings ratio of -28.17 and a beta of 2.07.
A number of hedge funds and other institutional investors have recently bought and sold shares of BLUE. Schwab Charles Investment Management Inc. boosted its position in bluebird bio by 51.9% during the third quarter. Schwab Charles Investment Management Inc. now owns 266,693 shares of the biotechnology company’s stock worth $36,631,000 after purchasing an additional 91,161 shares during the period. Tocqueville Asset Management L.P. boosted its position in bluebird bio by 78.0% during the third quarter. Tocqueville Asset Management L.P. now owns 55,690 shares of the biotechnology company’s stock worth $7,649,000 after purchasing an additional 24,400 shares during the period. Great West Life Assurance Co. Can boosted its position in bluebird bio by 22.7% during the third quarter. Great West Life Assurance Co. Can now owns 5,531 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 1,022 shares during the period. Janus Henderson Group PLC bought a new position in bluebird bio during the second quarter worth about $5,252,000. Finally, California Public Employees Retirement System boosted its position in bluebird bio by 1.5% during the third quarter. California Public Employees Retirement System now owns 86,100 shares of the biotechnology company’s stock worth $11,826,000 after purchasing an additional 1,300 shares during the period.
In related news, insider Nick Leschly sold 117,500 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $184.08, for a total transaction of $21,629,400.00. Following the completion of the sale, the insider now owns 293,232 shares in the company, valued at $53,978,146.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Davidson sold 4,000 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $202.36, for a total transaction of $809,440.00. The disclosure for this sale can be found here. Insiders have sold 200,280 shares of company stock valued at $37,818,846 in the last 90 days. 3.90% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “FY2017 Earnings Estimate for bluebird bio Inc Issued By Leerink Swann (NASDAQ:BLUE)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/13/bluebird-bio-inc-blue-expected-to-earn-fy2017-earnings-of-6-86-per-share.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Get a free copy of the Zacks research report on bluebird bio (BLUE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.